I-Mab to Participate in September Investor Conferences
Rhea-AI Summary
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in two major investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference from September 3-5, 2025, participating in one-on-one meetings. Additionally, I-Mab will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:30 AM ET, which will include both a company presentation and one-on-one meetings. The presentation webcast will be available on I-Mab's website for 90 days.
Positive
- None.
Negative
- None.
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the following upcoming investor conferences in September, 2025:
Conference details are as follows:
Cantor Global Healthcare Conference
Format: One-on-one meetings
Date: September 3-5, 2025
H.C. Wainwright 27th Annual Global Investment Conference
Format: Company presentation and one-on-one meetings
Date: Wednesday, September 10, 2025
Time: 9:30 AM ET
Webcast Link: Here
The webcast of the company presentation will be accessible from News & Events page of the I-Mab website for 90 days.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn.
| I-Mab Investor & Media Contacts |
| PJ Kelleher |
| LifeSci Advisors |
| +1-617-430-7579 |
| pkelleher@lifesciadvisors.com |
| IR@imabbio.com |
FAQ
When is I-Mab (IMAB) presenting at the H.C. Wainwright Conference in September 2025?
Which investor conferences will I-Mab (IMAB) attend in September 2025?
How can investors access I-Mab's presentation at the H.C. Wainwright Conference?
What type of meetings will I-Mab participate in at the Cantor Global Healthcare Conference?
